PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher Holdings Ltd. announced they have canceled a planned meeting with the FDA after receiving satisfactory preliminary responses regarding their Ketamine product’s application. The company is addressing minor deficiencies noted by the FDA and plans to resubmit necessary information by January 2025.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.